LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Items 101–200 of 1,000
LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling
Gao, Y., Xiao, Q., Ma, H., Li, L., Liu, J., Feng, Y., Fang, Z., Wu, J., Han, X., Zhang, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004952107 · Cited by 187
“We have previously shown that loss of function ofLkb1 promoted lung cancer progression and metastasis in mouse model driven by Kras mutant (6).”
BackgroundMethodSelf-citationUnni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S.-Q., & Varmus, H. (2015) · eLife · doi:10.7554/elife.06907 · Cited by 190
“Our analysis also revealed that mutations in a few genes—such as STK11 (also known as LKB1) and ATM, genes known to co-operate with mutant KRAS during lung tumorigenesis (Ji et al., 2007; Efeyan et al., 2009)—are positively associated with KRAS mutations (Figure 1C).”
BackgroundGlutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Best, S. A., Gubser, P. M., Sethumadhavan, S., Kersbergen, A., Negrón Abril, Y. L., Goldford, J., Sellers, K., Abeysekera, W., Garnham, A. L., McDonald, J. A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.003 · Cited by 179
CAS proteins in normal and pathological cell growth control
Tikhmyanova, N., Little, J. L., & Golemis, E. A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0213-1 · Cited by 187
“In human lung adenocarcinomas, NEDD9 expression is upregulated upon loss of the tumor suppressor STK11/LKB1, with this expression reversed upon reexpression of LKB1 [238].”
Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
Seguin, L., Durandy, M., & Feral, C. C. (2022) · Cancers · doi:10.3390/cancers14071759 · Cited by 171
“LKB1 inactivation leads to the development of a mixture of adenocarcinoma, adenosquamous carcinoma and squamous cell carcinomas in mice [62,63].”
BackgroundAlgire, C., Amrein, L., Bazile, M., David, S., Zakikhani, M., & Pollak, M. (2011) · Oncogene · doi:10.1038/onc.2010.483 · Cited by 181
“Somatic cell mutations of LKB1 are common in human lung, cervical and squamous cancers (Sanchez-Cespedes et al., 2002; Ji et al., 2007; Wingo et al., 2009) and a variety of LKB1 null neoplasms arise in patients with Peutz–Jeghers syndrome (van Lier et al.”
BackgroundMetabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells
Caino, M. C., Chae, Y. C., Vaira, V., Ferrero, S., Nosotti, M., Martin, N. M., Weeraratna, A., O’Connell, M., Jernigan, D., Fatatis, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67841 · Cited by 183
“Silencing of AMPK using independent siRNA sequences partially restored tumor cell motility in the presence of Gamitrinib (Figure 6A), suggesting that AMPK activation was required for this response. siRNA knock-down of the upstream AMPK activator and tumor suppressor, liver kinase B1 (LKB1) (Figure 6B and ref.”
InfluentialRewiring cell polarity signaling in cancer
Halaoui, R., & McCaffrey, L. (2015) · Oncogene · doi:10.1038/onc.2014.59 · Cited by 174
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Momcilovic, M., Bailey, S. T., Lee, J. T., Fishbein, M. C., Braas, D., Go, J., Graeber, T. G., Parlati, F., Demo, S., Li, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.002 · Cited by 181
“…staining of both ADC and SCC lung tumors from the autochthonous KrasG12D;Lkb1−/− (KL) genetically engineered mouse model (GEMM) that develops tumors with multiple histologies including both ADC and SCC tumors as previously described (Ji et al., 2007). squamous cell carcinoma, ADC – adenocarcinoma.”
ZEB1-responsive genes in non-small cell lung cancer
Gemmill, R. M., Roche, J., Potiron, V. A., Nasarre, P., Mitas, M., Coldren, C. D., Helfrich, B. A., Garrett-Mayer, E., Bunn, P. A., & Drabkin, H. A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.09.007 · Cited by 179
“ZEB1 has also been implicated in EMT associated with loss of function of LKB1 [38], now recognized as the most common gene alteration in lung adenocarcinomas [39; 40].”
BackgroundHardie, D. G. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390001 · Cited by 172
SIRT1 and AMPK in regulating mammalian senescence: A critical review and a working model
Wang, Y., Liang, Y., & Vanhoutte, P. M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.047 · Cited by 177
“Loss-of-function of LKB1 is frequently found in non-small cell lung carcinomas [134].”
BackgroundCell Cycle–Dependent Ciliogenesis and Cancer
Plotnikova, O. V., Golemis, E. A., & Pugacheva, E. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5838 · Cited by 171
“In lung cancer metastases dependent on loss of the tumor suppressor LKB1, HEF1 is strongly up-regulated (8); interestingly, LKB1 also”
BackgroundRAS: Striking at the Core of the Oncogenic Circuitry
Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174
“Activation of KRAS signaling along with homozygous deletion of LKB1 (also known as STK11 or serine/threonine kinase 11) promoted cancer progression and metastasis in non-small cell lung cancer models (74).”
BackgroundKey molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review
Perlikos, F., Harrington, K. J., & Syrigos, K. N. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.007 · Cited by 174
“[175] Ji H, Ramsey MR, Hayes DN, et al.”
BackgroundKim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Kim, J., Eskiocak, B., Chung, H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.041 · Cited by 172
“This mixed morphology is strikingly similar to that observed in spontaneous mouse lung tumors that arise as a consequence of Kras expression in an Lkb1 null background (Ji et al., 2007).”
Metformin: An anti-diabetic drug to fight cancer
Daugan, M., Dufaÿ Wojcicki, A., d’Hayer, B., & Boudy, V. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.006 · Cited by 164
Spatial mapping of mitochondrial networks and bioenergetics in lung cancer
Han, M., Bushong, E. A., Segawa, M., Tiard, A., Wong, A., Brady, M. R., Momcilovic, M., Wolf, D. M., Zhang, R., Petcherski, A., et al. (2023) · Nature · doi:10.1038/s41586-023-05793-3 · Cited by 163
Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion
Kreuzaler, P., Panina, Y., Segal, J., & Yuneva, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.021 · Cited by 163
“LKB1 is mutated in up to 35% of non-small cell lung cancer (NSCLC) and 20% of cervical carcinomas, making it the dominant tumor suppressor gene in this signaling axis affected in tumorigenesis [119,120].”
BackgroundNRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Singh, A., Daemen, A., Nickles, D., Jeon, S.-M., Foreman, O., Sudini, K., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1985 · Cited by 167
“At first glance, this may appear to contrast with the high prevalence of adeno-squamous and squamous histologies previously reported among Stk11Kras tumors (29, 40, 41).”
ResultLi, F., Han, X., Li, F., Wang, R., Wang, H., Gao, Y., Wang, X., Fang, Z., Zhang, W., Yao, S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.001 · Cited by 169
“, 2002), inactivation of Lkb1 in Kras;Lkb1 (KL) NSCLC mouse model dramatically accelerates lung tumor progression (Ji et al., 2007).”
InfluentialSelf-citationHIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications
Kellar, A., Egan, C., & Morris, D. (2015) · BioMed Research International · doi:10.1155/2015/621324 · Cited by 169
Morton, J. P., Jamieson, N. B., Karim, S. A., Athineos, D., Ridgway, R. A., Nixon, C., McKay, C. J., Carter, R., Brunton, V. G., Frame, M. C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.055 · Cited by 169
The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC
Hollstein, P. E., Eichner, L. J., Brun, S. N., Kamireddy, A., Svensson, R. U., Vera, L. I., Ross, D. S., Rymoff, T. J., Hutchins, A., Galvez, H. M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1261 · Cited by 168
“mutations, prompting intense study of genetically engineered mouse models of LKB1 loss coupled with Kras activation to understand how deregulation of these two genes drives tumor formation and growth, and response to therapy in lung cancer [4-9].”
BackgroundKoivunen, J. P., Kim, J., Lee, J., Rogers, A. M., Park, J. O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B. Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604469 · Cited by 163
“This study showed that lkb1 inactivation in combination with activating mutations of kras using inducible promoters in the lung was associated with decreased survival compared with kras mutation alone (Ji et al, 2007).”
BackgroundSelf-citationMolecular Pathways: Is AMPK a Friend or a Foe in Cancer?
Hardie, D. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3300 · Cited by 161
“non-small cell lung cancer [≈30% (39, 40)] and cervical cancer [≈20% (41)], it appears to be less 124 frequent in most other cancers, including breast cancer.”
BackgroundThe aryl hydrocarbon receptor system
Barouki, R., Aggerbeck, M., Aggerbeck, L., & Coumoul, X. (2012) · dmdi · doi:10.1515/dmdi-2011-0035 · Cited by 154
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 161
Self-citationKrasG12D and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung
Maeda, Y., Tsuchiya, T., Hao, H., Tompkins, D. H., Xu, Y., Mucenski, M. L., Du, L., Keiser, A. R., Fukazawa, T., Naomoto, Y., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64048 · Cited by 163
“Kras mutation in combination with p53, p16INK4a, or Lkb1 deletion leads to lung tumor metastasis in mouse models (48).”
SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis
Cheng, H., Liu, P., Wang, Z. C., Zou, L., Santiago, S., Garbitt, V., Gjoerup, O. V., Iglehart, J. D., Miron, A., Richardson, A. L., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000369 · Cited by 159
LKB1 Regulates Pancreatic β Cell Size, Polarity, and Function
Granot, Z., Swisa, A., Magenheim, J., Stolovich-Rain, M., Fujimoto, W., Manduchi, E., Miki, T., Lennerz, J. K., Stoeckert, C. J., Meyuhas, O., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.010 · Cited by 154
Self-citationPancreatic Lkb1 Deletion Leads to Acinar Polarity Defects and Cystic Neoplasms
Hezel, A. F., Gurumurthy, S., Granot, Z., Swisa, A., Chu, G. C., Bailey, G., Dor, Y., Bardeesy, N., & DePinho, R. A. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01621-07 · Cited by 151
“With respect to tumor suppression, Lkb1 heterozygous mice develop gastrointestinal polyps associated with deregulated AMPK-TSC-mTOR signaling, and concurrent mutation of the RAS oncogene and deletion of lkb1 in the lung lead to adenocarcinoma formation (5, 21 , 41).”
BackgroundSelf-citationOuyang, H., Gore, J., McElyea, S. D., & Korc, M. (2013) · Oncogene · doi:10.1038/onc.2013.405 · Cited by 167
“RAP2A has been implicated in cell adhesion and is induced by LKB1, whose loss of function is associated with altered cell polarity and enhanced metastases in lung cancer (63,64).”
Targeting AMPK: A new therapeutic opportunity in breast cancer
Hadad, S. M., Fleming, S., & Thompson, A. M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.007 · Cited by 174
Goodwin, J., Neugent, M. L., Lee, S. Y., Choe, J. H., Choi, H., Jenkins, D. M. R., Ruthenborg, R. J., Robinson, M. W., Jeong, J. Y., Wake, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15503 · Cited by 149
Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?
El-Telbany, A., & Ma, P. C. (2012) · Genes & Cancer · doi:10.1177/1947601912465177 · Cited by 177
Sivakumar, S., Moore, J. A., Montesion, M., Sharaf, R., Lin, D. I., Colón, C. I., Fleischmann, Z., Ebot, E. M., Newberg, J. Y., Mills, J. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0620 · Cited by 175
Liu, Y., Marks, K., Cowley, G. S., Carretero, J., Liu, Q., Nieland, T. J. F., Xu, C., Cohoon, T. J., Gao, P., Zhang, Y., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0015 · Cited by 157
Self-citationNew Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent
Leone, A., Gennaro, E. D., Bruzzese, F., Avallone, A., & Budillon, A. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_21 · Cited by 161
“The LKB1 gene exhibits loss of function mutations in approximately 30 % of non-small-cell lung cancers and in 20 % of cervical cancers [40, 83].”
BackgroundKwon, M.-C., & Berns, A. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.010 · Cited by 147
“, 2008) LSL-KrasG12D; Lkb1lox/lox Ad5-CMV-Cre Strongly augmented tumor growth and metastasis both Adenocarcinomas and Squamous cell carcinomas (Ji et al., 2007)”
BackgroundInfluentialLKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective
Ciccarese, F., Zulato, E., & Indraccolo, S. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8730816 · Cited by 158
Nilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4307 · Cited by 146
NEDD9 Promotes Oncogenic Signaling in Mammary Tumor Development
Izumchenko, E., Singh, M. K., Plotnikova, O. V., Tikhmyanova, N., Little, J. L., Serebriiskii, I. G., Seo, S., Kurokawa, M., Egleston, B. L., Klein–Szanto, A. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0795 · Cited by 149
“DNA amplification or transcriptional up-regulation of the NEDD9 gene, leading to elevated expression of the NEDD9 protein, has been reported as a potent regulator of cancer progression, invasion, and metastasis in melanoma (14) and glioblastoma (15) and linked to metastasis of LKB1 / lung tumors (16).”
BackgroundThe hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer
Kim, J., Lee, H. M., Cai, F., Ko, B., Yang, C., Lieu, E. L., Muhammad, N., Rhyne, S., Li, K., Haloul, M., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00316-0 · Cited by 142
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
Self-citationHIF2α cooperates with RAS to promote lung tumorigenesis in mice
Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., Jackson, A. L., Nikolinakos, P., Ospina, B., Naumov, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38443 · Cited by 141
Self-citationLKB1 and AMPK in cell polarity and division
Williams, T., & Brenman, J. E. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.01.008 · Cited by 156
Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK
Tolcher, A. W., Khan, K., Ong, M., Banerji, U., Papadimitrakopoulou, V., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 137
“Furthermore, there may be mechanisms independent of PI3K and MEK that lead to maintenance of cellular proliferation, such as upregulation of p21-activated kinase (30) or LKB1 mutations (31).”
BackgroundRogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 147
“8) 7,22,32,33 .”
The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?
Vara-Ciruelos, D., Russell, F. M., & Hardie, D. G. (2019) · Open Biology · doi:10.1098/rsob.190099 · Cited by 135
Deng, J., Thennavan, A., Dolgalev, I., Chen, T., Li, J., Marzio, A., Poirier, J. T., Peng, D. H., Bulatovic, M., Mukhopadhyay, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00208-6 · Cited by 140
Self-citationIntegrins and Cell Metabolism: An Intimate Relationship Impacting Cancer
Ata, R., & Antonescu, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010189 · Cited by 136
“The AMPK activator LKB1 is a potent tumour suppressor [117].”
BackgroundPrognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
Yu, H. A., Sima, C. S., Shen, R., Kass, S., Gainor, J., Shaw, A., Hames, M., Iams, W., Aston, J., Lovly, C. M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000432 · Cited by 137
“Preclinical data indicate that loss of LKB1 leads to a more aggressive tumor phenotype, with short tumor latency and greater rate of metastasis.(37) The presence of concurrent mutations may also have treatment implications as preclinical data suggest concurrent LKB1 inactivation alters downstream signaling and sensiti…”
BackgroundCross-cancer profiling of molecular alterations within the human autophagy interaction network
Lebovitz, C. B., Robertson, A. G., Goya, R., Jones, S. J., Morin, R. D., Marra, M. A., & Gorski, S. M. (2015) · Autophagy · doi:10.1080/15548627.2015.1067362 · Cited by 132
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.015 · Cited by 132
Myc Is a Metastasis Gene for Non-Small-Cell Lung Cancer
Rapp, U. R., Korn, C., Ceteci, F., Karreman, C., Luetkenhaus, K., Serafin, V., Zanucco, E., Castro, I., & Potapenko, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006029 · Cited by 129
“A number of genes and gene products have been identified that positively or negatively affect the probability of established human tumor cell lines to metastasize [2,3,4].”
BackgroundFenofibrate prevents skeletal muscle loss in mice with lung cancer
Goncalves, M. D., Hwang, S., Pauli, C., Murphy, C. J., Cheng, Z., Hopkins, B. D., Wu, D., Loughran, R. M., Emerling, B. M., Zhang, G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714703115 · Cited by 135
“Mice were started on a 0.2% fenofibrate (Feno) diet 6 wk following the induction of NSCLC and changes in body weight and food intake were measured.”
BackgroundMethodInfluentialThe mTOR–S6K pathway links growth signalling to DNA damage response by targeting RNF168
Xie, X., Hu, H., Tong, X., Li, L., Liu, X., Chen, M., Yuan, H., Xie, X., Li, Q., Zhang, Y., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-017-0033-8 · Cited by 133
“To further investigate the pathological association of LKB1 loss with RNF168 expression and DDR, we examined mouse tumor cells isolated from Kras G12D /p53 −/− and Kras G12D / Lkb1 −/− non–small cell lung cancer (NSCLC) mouse models 31–33 .”
Self-citationDavies, E. J., Dong, M., Gutekunst, M., Närhi, K., van Zoggel, H. J. A. A., Blom, S., Nagaraj, A., Metsalu, T., Oswald, E., Erkens-Schulze, S., et al. (2015) · Scientific Reports · doi:10.1038/srep17187 · Cited by 121
Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 138
“Such events include activation of the Wnt/β-catenin pathway [7], loss of function of PTEN [8], c-Myc signaling dependent activation [9], and loss of LKB1 signaling [10].”
BackgroundHaplo‐insufficiency: a driving force in cancer
Berger, A. H., & Pandolfi, P. P. (2011) · The Journal of Pathology · doi:10.1002/path.2800 · Cited by 124
LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma
Liu, W., Monahan, K. B., Pfefferle, A. D., Shimamura, T., Sorrentino, J., Chan, K. T., Roadcap, D. W., Ollila, D. W., Thomas, N. E., Castrillon, D. H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.048 · Cited by 127
“Although we also noted increased expression of Nedd9 and Vegf-c in both tumor types (data not shown), the most reliably upregulated gene associated with LKB1 loss in cell lines and primary tumors from both tumor types was CD24 (“CD24a” in the mouse, Figure S6A; Ji et al., 2007).”
InfluentialSelf-citationReungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 136
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14922 · Cited by 127
“Importantly, cutoff settings remained the same for ADC and SCC images from the same slide, allowing direct comparison of staining intensities in the mixed adenosquamous cases.”
InfluentialSelf-citationMir-155 promotes cervical cancer cell proliferation through suppression of its target gene LKB1
Lao, G., Liu, P., Wu, Q., Zhang, W., Liu, Y., Yang, L., & Ma, C. (2014) · Tumor Biology · doi:10.1007/s13277-014-2479-7 · Cited by 130
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K., & Pao, W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 123
“pressing oncogenic Kras in the lung accelerated tumor onset, and metastases were observed in two thirds of the mice examined.(69) Fi-”
BackgroundRacial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer
Schabath, M. B., Cress, W. D., & Muñoz-Antonia, T. (2016) · Cancer Control · doi:10.1177/107327481602300405 · Cited by 140
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
Gill, R. K., Yang, S.-H., Meerzaman, D., Mechanic, L. E., Bowman, E. D., Jeon, H.-S., Roy Chowdhuri, S., Shakoori, A., Dracheva, T., Hong, K.-M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.98 · Cited by 126
“Cooperation between LKB1 and K-ras was observed in using somatically activated K-ras-driven mouse model of lung cancer (Ji et al., 2007).”
MethodContreras, C. M., Akbay, E. A., Gallardo, T. D., Haynie, J. M., Sharma, S., Tagao, O., Bardeesy, N., Takahashi, M., Settleman, J., Wong, K.-K., et al. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004440 · Cited by 125
“In human cancers, the frequency of single-copy allelic loss at chromosome 19p spanning the LKB1 locus (without inactivation of the second allele) has been interpreted as possible evidence for a haploinsufficient tumor suppressor function (Hezel and Bardeesy, 2008; Ji et al., 2007).”
BackgroundSelf-citationMapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice
Rogers, Z. N., McFarland, C. D., Winters, I. P., Seoane, J. A., Brady, J. J., Yoon, S., Curtis, C., Petrov, D. A., & Winslow, M. M. (2018) · Nature Genetics · doi:10.1038/s41588-018-0083-2 · Cited by 132
Gao, Y., Zhang, W., Han, X., Li, F., Wang, X., Wang, R., Fang, Z., Tong, X., Yao, S., Li, F., et al. (2014) · Nature Communications · doi:10.1038/ncomms5629 · Cited by 123
Self-citationYAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting
Sardo, F. L., Strano, S., & Blandino, G. (2018) · Cancers · doi:10.3390/cancers10050137 · Cited by 130
“Accordingly, in NSCLC cell lines, LKB1 represses the expression of pro-metastatic genes [126] or pro-survival genes [83], and its lower expression in patients correlates with advanced disease [128].”
BackgroundNEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension
Samokhin, A. O., Stephens, T., Wertheim, B. M., Wang, R., Vargas, S. O., Yung, L., Cao, M., Brown, M. G., Arons, E., Dieffenbach, P. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap7294 · Cited by 135
Goodwin, J. M., Svensson, R. U., Lou, H. J., Winslow, M. M., Turk, B. E., & Shaw, R. J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.06.021 · Cited by 121
“Since Lkb1 deficiency enhances metastatic potential in Kras lung tumors (Ji et al., 2007), this is a specific context in which Snail could be mediating some of the prometastatic effects of loss of Lkb1.”
InfluentialInhibition of Gastric Cancer Invasion and Metastasis by PLA2G2A , a Novel β-Catenin/TCF Target Gene
Ganesan, K., Ivanova, T., Wu, Y., Rajasegaran, V., Wu, J., Lee, M. H., Yu, K., Rha, S. Y., Chung, H. C., Ylstra, B., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6517 · Cited by 119
“NEDD9 is another recently identified metastasis gene that may function as a ‘‘metastatic hub’’ among cancer signaling pathways (20, 36, 37).”
BackgroundDevelopment of Selective Covalent Janus Kinase 3 Inhibitors
Tan, L., Akahane, K., McNally, R., Reyskens, K. M. S. E., Ficarro, S. B., Liu, S., Herter-Sprie, G. S., Koyama, S., Pattison, M. J., Labella, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00710 · Cited by 122
“However, bulky and hydrophobic substituents resulted in decreased MLM stability (37, 38).”
BackgroundSelf-citationESFAHANIAN, N., SHAKIBA, Y., NIKBIN, B., SORAYA, H., MALEKI-DIZAJI, N., GHAZI-KHANSARI, M., & GARJANI, A. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.753 · Cited by 120
“It has been suggested that LKB1 is a critical barrier to pulmonary tumorigenesis, differentiation and metastasis (10).”
BackgroundAurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
Do, T.-V., Xiao, F., Bickel, L. E., Klein-Szanto, A. J., Pathak, H. B., Hua, X., Howe, C., O'Brien, S. W., Maglaty, M., Ecsedy, J. A., et al. (2014) · Oncogene · doi:10.1038/onc.2012.632 · Cited by 115
The double-edged sword of AMPK signaling in cancer and its therapeutic implications
Jeon, S.-M., & Hay, N. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0549-z · Cited by 112
“Since previous studies have shown that the combination of K-Ras activation and LKB1 deficiency developed lung cancer (Ji et al. 2007), it would be interesting to investigate how K-Ras activation can compensate for the loss of LKB1-induced metabolic adaptation in K-Ras/LKB1 mutated lung cancers.”
Abstract 275: Burkitt lymphoma cells express GLI1 but are not responsive to Hedgehog signaling
Yoon, J. W., Gallant, M. L., Lamm, M. L. G., Leong, K.-F., Iannaccone, P. M., & Walterhouse, D. O. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-275 · Cited by 120
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis
Katajisto, P., Vaahtomeri, K., Ekman, N., Ventelä, E., Ristimaki, A. P., Bardeesy, N. M., Feil, R., DePinho, R. A., & Mäkelä, T. P. (2008) · Nature Genetics · doi:10.1038/ng.98 · Cited by 117
Self-citationBhatt, V., Khayati, K., Hu, Z. S., Lee, A., Kamran, W., Su, X., & Guo, J. Y. (2019) · Genes & Development · doi:10.1101/gad.320481.118 · Cited by 115
“Intranasal delivery of both Adenoviral-Cre and Lenti-Cre can successfully induce Kras-driven NSCLC in GEMMs (DuPage et al. 2009; Gierut et al. 2014; Platt et al. 2014).”
BackgroundInfluentialInactivation of AMPK alters gene expression and promotes growth of prostate cancer cells
Zhou, J., Huang, W., Tao, R., Ibaragi, S., Lan, F., Ido, Y., Wu, X., Alekseyev, Y. O., Lenburg, M. E., Hu, G.-F., et al. (2009) · Oncogene · doi:10.1038/onc.2009.63 · Cited by 112
“In addition, somatic mutations of the LKB1 gene have been found in several other cancers, for example, in 34% of lung adenocarcinomas, 19% of squamous cell carcinomas and other cancers (Su et al., 1999; Ikediobi et al., 2006; Ji et al., 2007).”
Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3112 · Cited by 115
“Transition 22 (18) 20 (65) KRAS mutation”
BackgroundResultInfluentialAnoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies
Wang, J., Luo, Z., Lin, L., Sui, X., Yu, L., Xu, C., Zhang, R., Zhao, Z., Zhu, Q., An, B., et al. (2022) · Cancers · doi:10.3390/cancers14194791 · Cited by 125
Kim, K. W., Moretti, L., Mitchell, L., Jung, D. K., & Lu, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0589 · Cited by 122
“Among the mechanisms known to restrict auto‐ phagy, a relevant example is the association of NSCLC with mutations in LKB1 tumor suppressor, which negatively regulates mTOR signaling and is involved in the stimulation of autophagy (26).”
Loss of Lkb1 Provokes Highly Invasive Endometrial Adenocarcinomas
Contreras, C. M., Gurumurthy, S., Haynie, J. M., Shirley, L. J., Akbay, E. A., Wingo, S. N., Schorge, J. O., Broaddus, R. R., Wong, K.-K., Bardeesy, N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5014 · Cited by 108
“We show that Lkb1 functions as an endometrial cancer invasion gene, consistent with a recently described mouse model of lung cancer where Lkb1 deficiency conferred significantly increased mortality (32).”
Self-citationNana-Sinkam, S. P., & Croce, C. M. (2014) · Genome biology · doi:10.1186/s13059-014-0445-8 · Cited by 125
“functions as a tumor suppressor [79].”
The Pivotal Role of IKKα in the Development of Spontaneous Lung Squamous Cell Carcinomas
Xiao, Z., Jiang, Q., Willette‐Brown, J., Xi, S., Zhu, F., Burkett, S. S., Back, T. C., Song, N., Datla, M., Sun, Z., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.009 · Cited by 119
Self-citationUncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E
Esteve-Puig, R., Canals, F., Colomé, N., Merlino, G., & Recio, J. Á. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004771 · Cited by 115
“Importantly, sporadic mutations in the lkb1 gene have been documented in cancers of the breast, pancreas, lung, prostate, cervical and ovary as well as in Peutz-Jeghers syndrome, a rare disorder characterized by the appearance of intestinal polyps and mucocutaneous melanocytic macules [27,28,29,30,31].”
BackgroundTargeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Liu, S., Li, S., Hai, J., Wang, X., Chen, T., Quinn, M. M., Gao, P., Zhang, Y., Ji, H., Cross, D. A. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1875 · Cited by 130
“We also examined markers and found these HW tumors showed adenocarcinoma features with positive staining for TTF1 and low expression of SOX2 and p63(13,35,41) (Fig.”
BackgroundSelf-citationDrug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting
Li, B., Li, Q., Mo, J., & Dai, H. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00051 · Cited by 125
“These findings establish that LKB1 suppresses lung tumorigenesis through at least three independent mechanisms influencing tumor initiation, differentiation, and metastasis (Ji et al., 2007).”
BackgroundMechanisms of Tumor Cell–Intrinsic Immune Evasion
Spranger, S., & Gajewski, T. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 108
“A striking feature of immunotherapy is the durability of clinical benefit in many instances, even after drug administration has been discontinued, a phenomenon that has already pushed anti-PD-1/PD-L1 to the frontline indication for melanoma, NSCLC, and bladder cancer.”
BackgroundInfluentialOncosuppressive Functions of Autophagy
Morselli, E., Galluzzi, L., Kepp, O., Mariño, G., Michaud, M., Vitale, I., Maiuri, M. C., & Kroemer, G. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3478 · Cited by 104
“STK11 (LKB1) Germline mutations cause Peutz-Jeghers’s syndrome; somatic ones are found in NSCLC AMPK activator; may also promote autophagy by stabilizing p27 (38, 88, 100, 141, 216, 248)”
Viau, A., Bienaimé, F., Lukas, K., Todkar, A. P., Knoll, M., Yakulov, T. A., Hofherr, A., Kretz, O., Helmstädter, M., Reichardt, W., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798615 · Cited by 104
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W.-Y., Ayeni, D. O., Hastings, K., Choi, J., Wurtz, A., Andrejka, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1385 · Cited by 119
Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis
Wu, W. K. K., Wang, X., Cheng, A. S. L., Luo, M. X. M., Ng, S. S. M., To, K. F., Chan, F. K. L., Cho, C. H., Sung, J. J. �., & Yu, J. Q. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.009 · Cited by 115
“[57] Ji H, Ramsey MR, Hayes DN, Fan C, et al.”
BackgroundAn LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Murray, C. W., Brady, J. J., Tsai, M. K., Li, C., Winters, I. P., Tang, R., Andrejka, L., Ma, R. K., Kunder, C. A., Chu, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1237 · Cited by 111
“Gene expression data derived from tumors in humans and genetically engineered mice as well as human cancer cell lines under accession numbers GSE6135, GSE51266, GSE69747, GSE32863, GSE26939, GSE21581, GSE69552, GSE72094, GSE61913, GSE63882 were acquired from NCBI Gene Expression Omnibus using the GEOquery package (7,2…”
BackgroundMethodInfluentialLung Cancer: Are we up to the Challenge?
Esposito, L., Conti, D., Ailavajhala, R., Khalil, N., & Giordano, A. (2010) · Current Genomics · doi:10.2174/138920210793175903 · Cited by 115
“Another important tumor suppressor gene is LKB1, whose loss-of-function mutation/deletion is observed in 30% lung adenocarcinomas and 20% of squamous cell carcinomas [33, 34].”
Background
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.